FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971745157> ?p ?o ?g. }

• W2971745157 abstract "3027 Background: Malignant pleural or peritoneal effusions are frequently developed in the late-stage malignant tumors in chest or abdominal cavity. Various drainage methods and intra-cavity chemotherapy have transient and limited benefits. Here we evaluated the role of recombinant adenoviral human p53 gene (rAd-p53) infusion for patients with malignant pleural or peritoneal effusions. Methods: Thirty-two patients with historically diagnosed malignant pleural (18 cases) or peritoneal (14 cases) effusions, 19 males and 13 females with an average age of 61 years old (37–80 years), were included this study. The malignant pleural effusions were caused by primary lung cancers (8 cases), lung metastatic tumors (4 cases), breast cancers (3 cases), pleural mesothelioma (2 cases), lymphoma (1 cases), and the peritoneal effusions were caused by ovarian cancers (5 cases), primary liver cancers (4 cases), liver metastatic tumors (2 cases), colon cancer (1 case), gastric cancer (1 case), and prostate cancer (1 case). After draining most of the fluids, 4×10 12 viral particles (VP) of rAd-p53 diluted into 1,000 ml of saline solution for intra-abdominal cavity infusion and 2×10 12 VP of rAd-p53 diluted into 500 ml of saline solution for intra-chest cavity infusion, were given weekly for 4 weeks. The response rate was evaluated. The complete response is defined as the complete disappearance of pleural or peritoneal fluid and negative cytologic findings for >4 weeks, and the partial response is defined as a decrease over 50% of the fluid without the need of drainage and negative cytologic findings for >4 weeks. Results: The pleural effusion showed a complete response in 6 patients (33.3%) and a partial response in 6 patients (33.3%). The peritoneal effusion had a complete response in 3 patients (21.4%) and a partial response in 7 patients (50.0%). The overall response rate was 68.8% (22/32). The symptoms associated with the malignant effusion relieved in 27 patients (84.4%). There were no serious side effects observed except for self-limited fever found in all the cases. Conclusions: Intra-abdominal or chest cavity infusion of rAd-p53 is a safe and effective treatment for some malignant pleural or peritoneal effusions." @default.
• W2971745157 created "2019-09-12" @default.
• W2971745157 creator A5058710911 @default.
• W2971745157 date "2013-05-20" @default.
• W2971745157 modified "2023-09-27" @default.
• W2971745157 title "Recombinant adenoviral human p53 gene infusion in treatment of malignant pleural effusions and malignant ascites." @default.
• W2971745157 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.3027" @default.
• W2971745157 hasPublicationYear "2013" @default.
• W2971745157 type Work @default.
• W2971745157 sameAs 2971745157 @default.
• W2971745157 citedByCount "0" @default.
• W2971745157 crossrefType "journal-article" @default.
• W2971745157 hasAuthorship W2971745157A5058710911 @default.
• W2971745157 hasConcept C104317684 @default.
• W2971745157 hasConcept C111599444 @default.
• W2971745157 hasConcept C126322002 @default.
• W2971745157 hasConcept C142724271 @default.
• W2971745157 hasConcept C143998085 @default.
• W2971745157 hasConcept C2776232967 @default.
• W2971745157 hasConcept C2779634585 @default.
• W2971745157 hasConcept C2780496750 @default.
• W2971745157 hasConcept C40767141 @default.
• W2971745157 hasConcept C502942594 @default.
• W2971745157 hasConcept C55493867 @default.
• W2971745157 hasConcept C71924100 @default.
• W2971745157 hasConcept C86803240 @default.
• W2971745157 hasConceptScore W2971745157C104317684 @default.
• W2971745157 hasConceptScore W2971745157C111599444 @default.
• W2971745157 hasConceptScore W2971745157C126322002 @default.
• W2971745157 hasConceptScore W2971745157C142724271 @default.
• W2971745157 hasConceptScore W2971745157C143998085 @default.
• W2971745157 hasConceptScore W2971745157C2776232967 @default.
• W2971745157 hasConceptScore W2971745157C2779634585 @default.
• W2971745157 hasConceptScore W2971745157C2780496750 @default.
• W2971745157 hasConceptScore W2971745157C40767141 @default.
• W2971745157 hasConceptScore W2971745157C502942594 @default.
• W2971745157 hasConceptScore W2971745157C55493867 @default.
• W2971745157 hasConceptScore W2971745157C71924100 @default.
• W2971745157 hasConceptScore W2971745157C86803240 @default.
• W2971745157 hasLocation W29717451571 @default.
• W2971745157 hasOpenAccess W2971745157 @default.
• W2971745157 hasPrimaryLocation W29717451571 @default.
• W2971745157 hasRelatedWork W1825569247 @default.
• W2971745157 hasRelatedWork W2011363354 @default.
• W2971745157 hasRelatedWork W2056290107 @default.
• W2971745157 hasRelatedWork W2081808907 @default.
• W2971745157 hasRelatedWork W2117710094 @default.
• W2971745157 hasRelatedWork W2210839557 @default.
• W2971745157 hasRelatedWork W2313873979 @default.
• W2971745157 hasRelatedWork W2379580165 @default.
• W2971745157 hasRelatedWork W2379595465 @default.
• W2971745157 hasRelatedWork W2388698884 @default.
• W2971745157 hasRelatedWork W2394198598 @default.
• W2971745157 hasRelatedWork W2406163656 @default.
• W2971745157 hasRelatedWork W2409147603 @default.
• W2971745157 hasRelatedWork W2413375420 @default.
• W2971745157 hasRelatedWork W2419409301 @default.
• W2971745157 hasRelatedWork W2435649590 @default.
• W2971745157 hasRelatedWork W2443289520 @default.
• W2971745157 hasRelatedWork W2474881893 @default.
• W2971745157 hasRelatedWork W2513622549 @default.
• W2971745157 hasRelatedWork W2614833387 @default.
• W2971745157 isParatext "false" @default.
• W2971745157 isRetracted "false" @default.
• W2971745157 magId "2971745157" @default.
• W2971745157 workType "article" @default.